Who can participate?
Patients of ages up to 21 years may participate in this study:
- Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines
- Patients must have high-risk neuroblastoma
What will happen in the study?
This is a
dose-escalation study of lenalidomide.
lenalidomide orally (PO) once daily (QD) on days 1-21, monoclonal antibody
Ch14.18 IV over 10 hours on days 8-11, and isotretinoin PO twice daily (BID) on
days 15-28 of dose levels 2-5. Treatment repeats every 28 days for up to 6
courses in the absence of disease progression or unacceptable toxicity.
After completion of
study treatment, patients are followed up periodically.